Oncternal Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc. (ticker: ONCT) is a U.S.-listed clinical-stage biotechnology company that traded on the NASDAQ market. For French-speaking investors, it fits the profile of a high-risk, event-driven micro-cap in healthcare, where valuation is driven primarily by clinical milestones, corporate actions, asset sales, and financing decisions rather than by recurring commercial revenue. The company was historically based in San Diego, California, United States, but its current website states that Oncternal is no longer operating in a normal business sense and provides a mailing address in Foxboro, Massachusetts for correspondence. ([oncternal.com](https://www.oncternal.com/?utm_source=openai)) Founded in 2013, Oncternal built its story around oncology and immuno-oncology drug development, targeting difficult-to-treat cancers and other serious diseases. Its lead asset has been OT-101, a TGF-beta inhibitor studied in oncology settings and, more recently, in viral respiratory disease-related applications. The company also advanced ONCT-534, an androgen receptor pathway program, alongside other research initiatives. This makes Oncternal a classic specialty biotech: a small company with a scientific pipeline rather than a mature product franchise, and with value creation tied to data generation, regulatory progress, and potential transaction opportunities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1260990/000095017023022709/2023_ars.pdf?utm_source=openai)) In competitive terms, the company operated in one of the most crowded and capital-intensive areas of the life sciences industry. Its position was not that of a large commercial oncology player, but rather that of a niche developer trying to establish differentiated proof-of-concept in areas where efficacy and safety data are critical. That means its competitive strength depended on intellectual property, trial design, and strategic execution, while its weakness was the usual biotech burden of funding needs, binary clinical risk, and limited operating scale. ([oncternal.com](https://www.oncternal.com/?utm_source=openai)) Recent corporate developments materially changed the investment case. On July 1, 2025, Oncternal announced the sale of select development programs, indicating a portfolio simplification and possible monetization of non-core assets. Earlier, in March 2025, the company disclosed its intention to voluntarily delist from NASDAQ and deregister with the SEC, a major step that typically reduces liquidity and public-market visibility. The company’s own website now emphasizes that it is no longer operating, underscoring that the story is no longer one of normal operating momentum but rather of restructuring and wind-down style corporate events. ([oncternal.com](https://www.oncternal.com/ONCT-Press-Release-1-July.pdf?utm_source=openai)) For investors, Oncternal Therapeutics should be viewed as a special-situation former oncology biotech, historically listed on NASDAQ in the United States, with the key questions centered on residual asset value, transaction outcomes, and any remaining SEC/corporate event disclosures rather than on traditional growth metrics. ([oncternal.com](https://www.oncternal.com/?utm_source=openai))